Gachon University Gil Hospital, 'Dream Cancer Treatment Device'A-BNCT phase 1 clinical trial is incomplete
Jul 25, 2024
Gachon University Gil Hospital (Hospital Director Kim Woo-kyung) developed an A-BNCT (boron neutrophil capture treatment device) and completed the phase 1 clinical trial and took a step closer to overcoming malignant glioblastoma, which has a cure rate of only 8.9% (5-year survival rate).
In Korea, a total of 1962 new glioblastoma patients were diagnosed in 2023. Glioblastoma is the most common tumor among malignant brain tumors, accounting for about 42% of glioblastoma, which accounts for the majority of neuroepithelial tumors. Treatment is very difficult because the tumor proliferation rate is fast and it penetrates into surrounding brain tissue and grows. Due to these characteristics, the survival rates of 1, 2, 3, and 5-year glioblastoma patients in Korea are only 47.2%, 20.0%, 13.0%, and 8.9%, respectively, according to the National Cancer Information Center. It is refractory cancer with a median survival period of 14 months and a 10-year survival rate of 5.3%.
Gachon University Gil Hospital has secured treatment stability by completing the first phase 1 clinical trial of A-BNCT, known as the 4th generation 'Dream Cancer Treatment Device' for the first time in Korea. In addition, it was evaluated as the world's leading medical institution in the related field by presenting the development process and clinical results at the recent World BNCT Conference held in Poland.
A-BNCT is a treatment that kills only tumor cells by irradiating neutrons to tumor cells that have ingested boron after injecting boron compounds into the body. Normal cells do not suffer any damage during the treatment process, so it is a near-perfect cancer treatment method in theory. It is a breakthrough cancer treatment method that can treat patients who have been difficult to treat with existing methods such as malignant brain tumors, recurrent cancers, or invasive cancers that are difficult to surgically resect. In addition, unlike other radiation treatments that need to be repeated several times, the treatment is completed with only one dose. In Korea, Gachon University Gil Hospital is undergoing clinical trials in collaboration with Da Won Medax and others with the support of the Ministry of Trade, Industry and Energy.
Gachon University Gil Hospital conducted a phase 1/2a clinical trial on six patients with glioblastoma, a malignant tumor, to secure stability in treatment. Phase 1 clinical trials were conducted on a total of six patients from December 2022 to January this year. In particular, two out of six treated patients are showing very good progress, two are in a condition similar to that of existing treatment, and two are difficult to compare with existing treatment due to a short follow-up period.
However, considering that all clinical subjects are patients with recurrent glioblastoma, it is evaluated as a significant treatment outcome. The first clinical patient has been in good health for 18 months, and most of the patients are showing good effects compared to existing treatment methods. Expectations for fundamental treatment of glioblastoma, an intractable tumor, are high.
Kim Woo-kyung, director of the hospital, said, `It is meaningful to secure stability in treatment for glioblastoma patients with the worst prognosis among malignant brain tumors.' `Gachon University Gil Hospital will become a world-class medical institution leading the BNCT field with excellent technology.'
Professor Lee Ki-taek of neurosurgery, who is in charge of this clinical trial, received favorable reviews by presenting the clinical results at the international conference '20th International Congress on Neutron Capture Therapy' held in Krakow, Poland from June 24 to 28, 2024. The event, which was held for the 20th time this year, is the largest academic conference in which experts from BNCT-related medical institutions, research institutes, companies, and others from around the world attend to share knowledge and experience and form a network.
Professor Lee Ki-taek said, "It has been confirmed that the first patient not only showed a very good prognosis, but also improved significantly compared to the existing treatment in terms of effectiveness. We will also proceed with the future clinical process for cancer patients who are difficult to treat."."
Gachon University Gil Hospital will continue patient observation and treatment as it has secured stability in this clinical trial, finalizing the phase 1 clinical trial and completing the submission of the case record (CSR). After that, it plans to enter phase 2 clinical trials within this year after examining the progress of the patients. In addition, in addition to glioblastoma covered in this clinical trial, the indication is expected to be expanded to intractable cancers such as head and neck cancer, malignant brain tumors, and skin melanoma.
In Korea, a total of 1962 new glioblastoma patients were diagnosed in 2023. Glioblastoma is the most common tumor among malignant brain tumors, accounting for about 42% of glioblastoma, which accounts for the majority of neuroepithelial tumors. Treatment is very difficult because the tumor proliferation rate is fast and it penetrates into surrounding brain tissue and grows. Due to these characteristics, the survival rates of 1, 2, 3, and 5-year glioblastoma patients in Korea are only 47.2%, 20.0%, 13.0%, and 8.9%, respectively, according to the National Cancer Information Center. It is refractory cancer with a median survival period of 14 months and a 10-year survival rate of 5.3%.
Gachon University Gil Hospital has secured treatment stability by completing the first phase 1 clinical trial of A-BNCT, known as the 4th generation 'Dream Cancer Treatment Device' for the first time in Korea. In addition, it was evaluated as the world's leading medical institution in the related field by presenting the development process and clinical results at the recent World BNCT Conference held in Poland.
A-BNCT is a treatment that kills only tumor cells by irradiating neutrons to tumor cells that have ingested boron after injecting boron compounds into the body. Normal cells do not suffer any damage during the treatment process, so it is a near-perfect cancer treatment method in theory. It is a breakthrough cancer treatment method that can treat patients who have been difficult to treat with existing methods such as malignant brain tumors, recurrent cancers, or invasive cancers that are difficult to surgically resect. In addition, unlike other radiation treatments that need to be repeated several times, the treatment is completed with only one dose. In Korea, Gachon University Gil Hospital is undergoing clinical trials in collaboration with Da Won Medax and others with the support of the Ministry of Trade, Industry and Energy.
Gachon University Gil Hospital conducted a phase 1/2a clinical trial on six patients with glioblastoma, a malignant tumor, to secure stability in treatment. Phase 1 clinical trials were conducted on a total of six patients from December 2022 to January this year. In particular, two out of six treated patients are showing very good progress, two are in a condition similar to that of existing treatment, and two are difficult to compare with existing treatment due to a short follow-up period.
However, considering that all clinical subjects are patients with recurrent glioblastoma, it is evaluated as a significant treatment outcome. The first clinical patient has been in good health for 18 months, and most of the patients are showing good effects compared to existing treatment methods. Expectations for fundamental treatment of glioblastoma, an intractable tumor, are high.
Kim Woo-kyung, director of the hospital, said, `It is meaningful to secure stability in treatment for glioblastoma patients with the worst prognosis among malignant brain tumors.' `Gachon University Gil Hospital will become a world-class medical institution leading the BNCT field with excellent technology.'
Professor Lee Ki-taek of neurosurgery, who is in charge of this clinical trial, received favorable reviews by presenting the clinical results at the international conference '20th International Congress on Neutron Capture Therapy' held in Krakow, Poland from June 24 to 28, 2024. The event, which was held for the 20th time this year, is the largest academic conference in which experts from BNCT-related medical institutions, research institutes, companies, and others from around the world attend to share knowledge and experience and form a network.
Professor Lee Ki-taek said, "It has been confirmed that the first patient not only showed a very good prognosis, but also improved significantly compared to the existing treatment in terms of effectiveness. We will also proceed with the future clinical process for cancer patients who are difficult to treat."."
Gachon University Gil Hospital will continue patient observation and treatment as it has secured stability in this clinical trial, finalizing the phase 1 clinical trial and completing the submission of the case record (CSR). After that, it plans to enter phase 2 clinical trials within this year after examining the progress of the patients. In addition, in addition to glioblastoma covered in this clinical trial, the indication is expected to be expanded to intractable cancers such as head and neck cancer, malignant brain tumors, and skin melanoma.
|
bellho@sportschosun.com
